460 — Sihuan Pharmaceutical Holdings Balance Sheet
0.000.00%
- HK$11.99bn
- HK$9.57bn
- CNY1.90bn
- 41
- 15
- 81
- 41
Annual balance sheet for Sihuan Pharmaceutical Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4,937 | 5,792 | 4,792 | 4,368 | 3,777 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 821 | 1,094 | 978 | 1,045 | 1,305 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6,404 | 7,741 | 6,550 | 6,204 | 5,718 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,841 | 4,093 | 2,998 | 2,842 | 2,635 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 13,044 | 14,496 | 12,141 | 11,535 | 10,532 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,443 | 2,502 | 2,533 | 4,107 | 3,310 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3,854 | 6,211 | 7,404 | 7,103 | 6,159 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 9,190 | 8,284 | 4,737 | 4,432 | 4,372 |
| Total Liabilities & Shareholders' Equity | 13,044 | 14,496 | 12,141 | 11,535 | 10,532 |
| Total Common Shares Outstanding |